Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model

Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model

A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources. This study assesses three approaches to DNL suppression in a newly developed dietary NASH mouse...

Full description

Bibliographic Details
Main Authors: Berangere Gapp, Marie Jourdain, Pauline Bringer, Benjamin Kueng, Delphine Weber, Arnaud Osmont, Stefan Zurbruegg, Judith Knehr, Rocco Falchetto, Guglielmo Roma, William Dietrich, Reginald Valdez, Nicolau Beckmann, Florian Nigsch, Arun J. Sanyal, Iwona Ksiazek
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1443

Similar Items

Similar Items